Long-term data in #GeparOLA trial demonstrated similar outcome when carboplatinum was exchanged by #Olaparib as part of the neoadjuvant chemotherapy when a #BRCA mutation was present but not in wt BRCA but HRD high tumor patients. #SABCS22
Full presentation: https://www.gbg.de/wAssets/docs/geparola/2022-SABCS_GeparOla-LongtimeFU.pdf

#GeparOLA compares pac/carbo vs. pac/Olaparib in OFS with HER-2 beg and HRD def #bcsm

🔹Carbo combo results in numerically higher iDFS, DDFS? And OS compared to olaparib combo.

🔹Particularly prominent improvement in BRCAwt

#SABCS22 @OncoAlert@twitter.com